Please login to the form below

Not currently logged in
Email:
Password:

Astex in $500m deal

Astex Therapeutics has signed a new research deal with Janssen Pharmaceutica, which could see the company earn close to $500m in royalty payments
Astex Therapeutics has signed a new research deal with Janssen Pharmaceutica, which could see the company earn close to $500m in royalty payments.

The agreement effectively grants Janssen Pharmaceutica, a US company owned by Johnson & Johnson, exclusive rights to develop compounds from Astex's fibroblast growth factor receptor (FGFR) inhibitor programme. Responsibility for clinical and pre-clinical R&D of the compounds will fall to Ortho Biotech Research & Development, a division of Janssen Pharmaceutica.

Astex now stands to receive $37.4m in upfront cash, equity payments, and research funding over a two-year period. The deal signals the creation of a novel drug discovery programme that is focused on developing treatments for cancer, with two specific research targets having already been set.

"This is another landmark agreement for Astex," said Harren Jhoti, CEO of Astex Therapeutics.

"This partnership is another testament to Astex's position as the leader in fragment-based drug discovery and the productivity generated by our platform."

The company says that these latest developments serve as proof of the efficacy of its proprietary drug discovery platform, Pyramid, which has generated one new cancer drug candidate for clinical testing per year since 2004.

Under the terms of the deal, Astex now has the right to commercialise FGFR products developed under the US collaboration.

9th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics